TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The FDA approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel patch, the first generic version of Climara Pro. It is applied once weekly and is approved for certain uses in women with an intact uterus; when it will be available and at what price were not specified in the FDA announcement.
The U.S. Food and Drug Administration approved the first generic version of Climara Pro, a hormone therapy patch applied once a week, for women with an intact uterus. The generic, made by Zydus Pharmaceuticals (USA) Inc., combines estradiol and levonorgestrel and is approved to treat moderate to severe menopause-related hot flashes and to prevent postmenopausal osteoporosis.
The FDA said the generic estradiol and levonorgestrel transdermal system is therapeutically equivalent to Climara Pro. Each patch delivers estradiol at 0.045 milligrams per day and levonorgestrel at 0.015 milligrams, according to the agency. The patch is applied once a week, rather than taken as a daily oral medication.
Both hormones are included in the same patch. The FDA said the progestogen, levonorgestrel, is included because the product is intended for women with an intact uterus; using estrogen without a progestogen can lead to endometrial hyperplasia, an abnormal thickening of the uterine lining. The agency’s approval covers the same specified uses as Climara Pro: treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis.
The FDA announcement lists possible adverse reactions occurring in at least 5% of users, including application-site reactions, vaginal bleeding, breast pain, back pain, depression and headache, as well as upper respiratory infection, pain and flu syndrome. It also lists conditions and histories for which the therapy is contraindicated, including certain cancers, unexplained abnormal genital bleeding, blood clots and some liver or clotting disorders. Patients should consult a qualified health professional about whether the medicine is appropriate for them.
A Second Source for Weekly Therapy
The approval adds a generic competitor to a branded patch used for two menopause-related indications. Generic medicines can contribute to competition and may expand access, but the FDA announcement did not provide a retail price, expected savings or evidence that this specific approval will reduce costs by a particular amount.
For patients prescribed this combination therapy, the product offers the same once-weekly delivery schedule as Climara Pro, according to the FDA’s therapeutic-equivalence finding. The agency’s Center for Drug Evaluation and Research director, Michael Davis, said weekly dosing may help patients manage treatment compared with daily oral medication. That is an attributed general claim; the release did not report adherence results for this generic product.
The approval is not a recommendation for every person experiencing menopause symptoms. The label’s indication is limited to women with an intact uterus for the stated uses, and the FDA lists serious contraindications. The product’s availability, price and individual suitability will shape its practical effect for patients.
estradiol levonorgestrel hormone patch
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Patch Combines Two Hormones
Climara Pro is a branded transdermal hormone therapy product. The newly approved generic contains estradiol, an estrogen, and levonorgestrel, a progestogen, delivered through the skin. This differs from estrogen-only patches commonly used in menopause treatment, the FDA said.
The agency explained that the progestogen component is included for women with an intact uterus to reduce the risk of endometrial hyperplasia associated with estrogen use alone. That does not remove the need to follow the product labeling or review risks with a clinician. The FDA announcement lists a range of contraindications, including breast cancer or a history of breast cancer, estrogen-dependent neoplasia, active or prior deep vein thrombosis or pulmonary embolism, certain arterial thromboembolic disease, liver disease and thrombophilic disorders.
The FDA described the approval as consistent with its effort to increase access to affordable medicines. It also noted that nine out of 10 prescriptions filled in the United States are for generic drugs. That national figure is broader context, not a forecast of the price or uptake of this particular patch.
““Menopause is a universal experience for women, and it can greatly affect a person’s quality of life. This approval makes effective treatment more accessible.””
— Kyle Diamantas, acting FDA commissioner
As an affiliate, we earn on qualifying purchases.
Price and Supply Not Yet Specified
The FDA announcement did not state when the generic will reach pharmacies, how widely it will be distributed or what it will cost. The agency directed readers to contact the manufacturer for availability information. Approval establishes that the generic is therapeutically equivalent to Climara Pro, but it does not establish a specific price reduction or guarantee that every pharmacy will stock it.
The release also does not provide a new clinical trial comparison, patient outcome data or an estimate of how many people may use the product. Its listed uses and safety information apply to the approved therapy; whether it is suitable for an individual depends on medical history and clinical assessment.
weekly hormone patch for menopause
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Manufacturer Availability and Pharmacy Access
Zydus Pharmaceuticals is the source identified by the FDA for information about the medicine’s availability. Patients and prescribers can also consult the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book, for the agency’s listing of approved drug products and therapeutic-equivalence information.
As distribution develops, the practical questions will be whether the generic is stocked locally, how its price compares with Climara Pro and whether insurers cover it. Patients should not switch hormone therapy or begin using the patch solely on the basis of the approval; they should discuss treatment choices and contraindications with a qualified health professional.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA approve?
The FDA approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel transdermal system, the first generic version of Climara Pro, according to its October 20, 2026 announcement.
Who is the patch approved for?
The approval covers women with an intact uterus for treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis. The medicine is not appropriate for everyone; the FDA lists multiple contraindications.
How often is the generic patch applied?
The patch is applied once a week. The FDA said the generic is therapeutically equivalent to Climara Pro, which has the same weekly schedule.
When will it be available, and how much will it cost?
The FDA release did not give a launch date or price. It advises contacting Zydus Pharmaceuticals for availability information; pharmacy stocking and patient costs may vary.
What side effects and restrictions did the FDA list?
Listed common adverse reactions include application-site reaction, vaginal bleeding, breast pain, back pain, depression and headache. Contraindications include certain cancers, unexplained abnormal genital bleeding, blood-clot conditions, liver disease and some clotting disorders. Patients should review the full labeling and consult a qualified health professional.
Source: primary
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
